Active Biotech AB (ST:ACTI) — Market Cap & Net Worth
Market Cap & Net Worth: Active Biotech AB (ACTI)
Active Biotech AB (ST:ACTI) has a market capitalization of $103.60 Million (Skr962.66 Million) as of June 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #19136 globally and #330 in its home market, demonstrating a -5.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Active Biotech AB's stock price Skr6.10 by its total outstanding shares 2636067170 (2.64 Billion). Review how much debt does Active Biotech AB carry to assess the company's total debt and financial obligations.
Active Biotech AB Market Cap History: 2015 to 2026
Active Biotech AB's market capitalization history from 2015 to 2026. Data shows growth from $2.33 Billion to $1.73 Billion (0.22% CAGR).
Active Biotech AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Active Biotech AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
55.30x
Active Biotech AB's market cap is 55.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.33 Billion | $16.27 Million | -$193.53 Million | 143.28x | N/A |
| 2016 | $1.80 Billion | $19.04 Million | -$59.58 Million | 94.31x | N/A |
| 2017 | $299.03 Million | $20.25 Million | -$108.79 Million | 14.77x | N/A |
| 2018 | $687.02 Million | $20.05 Million | -$36.88 Million | 34.26x | N/A |
| 2019 | $514.40 Million | $8.43 Million | -$36.07 Million | 61.06x | N/A |
| 2020 | $514.71 Million | $6.72 Million | -$32.12 Million | 76.54x | N/A |
| 2021 | $344.22 Million | $6.22 Million | -$49.88 Million | 55.30x | N/A |
Competitor Companies of ACTI by Market Capitalization
Companies near Active Biotech AB in the global market cap rankings as of June 19, 2026.
Key companies related to Active Biotech AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Active Biotech AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Active Biotech AB's market cap moved from $2.33 Billion to $ 1.73 Billion, with a yearly change of 0.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr1.73 Billion | +13150.00% |
| 2025 | Skr13.05 Million | -57.72% |
| 2024 | Skr30.86 Million | -76.17% |
| 2023 | Skr129.50 Million | -52.55% |
| 2022 | Skr272.90 Million | -20.72% |
| 2021 | Skr344.22 Million | -33.12% |
| 2020 | Skr514.71 Million | +0.06% |
| 2019 | Skr514.40 Million | -25.13% |
| 2018 | Skr687.02 Million | +129.75% |
| 2017 | Skr299.03 Million | -83.35% |
| 2016 | Skr1.80 Billion | -22.98% |
| 2015 | Skr2.33 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Active Biotech AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $103.60 Million USD |
| MoneyControl | $103.60 Million USD |
| MarketWatch | $103.60 Million USD |
| marketcap.company | $103.60 Million USD |
| Reuters | $103.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as… Read more